Bright! FRONTEO Official Blog

Bright! FRONTEO Official Blog

[Online Seminar held on March 3th] Re-streamed due to popular demand! The next global trend is anti-aging. New common sense for anti-aging and health led by AI drug discovery support

"Anti-aging is the next big thing after AI" - As generative AI has become more widespread in recent years, anti-aging is attracting attention as the next global trend. In the healthcare field, in addition to administering medicine, multifaceted approaches such as food, Chinese medicine, and exercise will become even more important in the future.
In this seminar, the developer of KIBIT Amanogawa, a research paper exploration AI that can discover the unknown from the known, will introduce new anti-aging possibilities revealed by AI analysis. In particular, he will focus on Klotho, a substance known to be closely related to anti-aging, and s-Klotho, which leaks into the blood and circulates throughout the body. He will explain through examples of research paper x AI analysis how mugwort as a food and exercise can activate this substance and contribute to the prevention and treatment of aging-related heart disease, diabetes, Alzheimer's disease, and other conditions.
*Please note that this seminar will be a recording of the seminar held on February 2th (Wednesday), excluding the opening and Q&A sessions.

Click here for registration and seminar details:https://lp.fronteo.com/BP-WBN-20250327-LSAI_Registration.html
 

Event Outline

[Date and time] Thursday, November 2025, 3 27:11~30:12

Format: Online (Zoom Webinars)

[Participation conditions]
We may decline applications from people using free email addresses, people in the same industry as us, and people whose affiliation is unknown. When accessing Zoom on the day, please enter the name and email address you provided when applying in the Zoom participation input field.


 
Speakers/panelist:

◎Lecturer
nakazono_square.jpg

FRONTEO Inc.
Director/CTO PhD (Science)
Hiroyoshi Toyoshiba

Ph.D. in Mathematics. Since 2000, he has participated in research on the carcinogenesis process through data analysis at the National Institute of Environmental Health Sciences (NIEHS). In 2006, he joined Takeda Pharmaceutical Company, where he served as a researcher in the bioinformatics field, head of bioinformatics at the Global Data Science Institute Japan site, and science fellow. In 2017, he joined FRONTEO to develop AI algorithms specialized in the field of life sciences. To date, various AI solutions based on these algorithms have been commercialized, including paper search, drug discovery support, dementia diagnosis support, and fall prediction. He has been appointed CTO of Life Science AI since 2019, and a director since 2024.


◎ Moderator and Q&A

nakazono_square.jpg
FRONTEO Inc.
Life Science AI Business Headquarters
AI drug discovery team manager
Go Nakazono

Majored in applied physics at Fukuoka University Faculty of Science.
Worked as a key account manager in BtoB business in the advertising industry.
In the pharmaceutical industry, he has experience in MR, marketing, academics, etc., mainly targeting rare diseases, blood diseases, and pediatric diseases. His previous job was as an area manager at Takeda Pharmaceutical Company.
Currently working on expanding the AI ​​drug discovery business at the Life Science AI Business Headquarters.

Share this article